C. Chipoy

Recent advances in the management of osteosarcoma and forthcoming therapeutic strategies

F. Gouin, F. Blanchard, F. Redini, 2007, Expert review of anticancer therapy.

RANKL/RANK/OPG: new therapeutic targets in bone tumours and associated osteolysis.

M. Padrines, S. Théoleyre, D. Heymann, 2004, Biochimica et biophysica acta.

Oncostatin M Induces Bone Loss and Sensitizes Rat Osteosarcoma to the Antitumor Effect of Midostaurin In vivo

D. Heymann, K. Mori, F. Blanchard, 2008, Clinical Cancer Research.

Histone deacetylase inhibitors: new drugs for the treatment of inflammatory diseases?

F. Blanchard, C. Chipoy, 2005, Drug discovery today.

Long term oncostatin M treatment induces an osteocyte-like differentiation on osteosarcoma and calvaria cells.

V. Ferré, D. Heymann, F. Blanchard, 2009, Bone.

Sensitization of osteosarcoma cells to apoptosis by oncostatin M depends on STAT5 and p53

S. Battaglia, L. Oliver, P. Juin, 2007, Oncogene.

Downregulation of Osteoblast Markers and Induction of the Glial Fibrillary Acidic Protein by Oncostatin M in Osteosarcoma Cells Require PKCδ and STAT3

C. Colombeix, F. Vallette, D. Heymann, 2004, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.